DCLK1: A Potential Drug Target and Biomarker (G9201)

Target Name: DCLK1

NCBI ID: G9201

DCLK1

DCLK1: A Potential Drug Target and Biomarker

DCLK1, also known as Doublecortin-like kinase 1, is a protein that is expressed in various tissues and cell types in the brain. It is a member of the superfamily of C kinases, which are known for their role in intracellular signaling. In recent Over the years, researchers have identified DCLK1 as a potential drug target and biomarker for various neurological and psychiatric disorders.

The DCLK1 gene was first identified in the mouse brain in 2004 by researchers at the University of California, San Diego. They found that DCLK1 was highly expressed in the cerebral cortical regions of mice and that it was involved in the development of several neurological behaviors , including anxiety, ungratefulness, and spatial navigation. The researchers also found that DCLK1 was overexpressed in the brains of mice with neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Since then, researchers have conducted several studies to determine the functions of DCLK1 in various brain regions and cellular processes. These studies have provided valuable insights into the role of DCLK1 in neuro development, behavior, and disease.

One of the most significant findings of these studies is that DCLK1 is involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. Synaptic plasticity is critical for the development and maintenance of neural circuits, and DCLK1 is thought to play a role in this process.

In addition to its role in synaptic plasticity, DCLK1 has also been shown to be involved in the regulation of neurotransmitter release and cell signaling. DCLK1 has been shown to interact with several neurotransmitter systems, including dopamine, serotonin, and GABA. It is also thought to play a role in the regulation of ion channels, which are responsible for the flow of electrical signals through neuron cells.

The potential drug target for DCLK1 is based on its involvement in several neurotransmitter systems and its expression in regions of the brain involved in neuro development and disease. One of the most promising compounds that has been shown to interact with DCLK1 is the drug rapamycin, which is an inhibitor of the activity of the protein SIRT1. Rapamycin has been shown to increase the levels of DCLK1 in the brain and to protect against its loss in neurodegenerative disorders.

Another potential drug target for DCLK1 is its role in the regulation of cell signaling. DCLK1 has been shown to interact with several signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth and differentiation. DCLK1 has also been shown to play a role in the regulation of cell survival, which is critical for the development and maintenance of neural circuits.

In addition to its potential drug targets, DCLK1 also has potential as a biomarker for several neurological and psychiatric disorders. The high expression of DCLK1 in the brains of mice with neurodegenerative disorders, as well as its involvement in the regulation of synaptic plasticity and neurotransmitter release , suggests that it may be a useful biomarker for these disorders.

In conclusion, DCLK1 is a protein that is involved in several critical processes in the brain, including synaptic plasticity, neurotransmitter release, and cell signaling. Its high expression in the brains of mice with neurodegenerative disorders makes it a potential drug target, and its potential as a biomarker for these disorders makes it an attractive target for future research. Further studies are needed to fully understand the role of DCLK1 in neuro development, behavior, and disease.

Protein Name: Doublecortin Like Kinase 1

Functions: Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain. May also participate in functions of the mature nervous system

The "DCLK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DCLK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets